Hematology & Medical Oncology

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Gastrointestinal Stromal Tumors 60%
3. Castration 47%
4. Neoplasms 39%
5. Imatinib Mesylate 35%
6. Mutation 34%
7. Docetaxel 32%
8. Androgens 31%
9. MDV 3100 30%
10. Therapeutics 29%
11. Drug Therapy 28%
12. Prostate-Specific Antigen 23%
13. Survival 22%
14. Calcitriol 17%
15. Acute Myeloid Leukemia 16%
16. Phosphotransferases 15%
17. Safety 15%
18. Progression-Free Survival 14%
19. Breast Neoplasms 14%
20. Placebos 13%
21. Protein-Tyrosine Kinases 13%
22. Leukemia 13%
23. Hemorrhage 12%
24. Prostate 12%
25. Sunitinib 12%
26. Transplants 12%
27. Fanconi Anemia 12%
28. Clinical Trials 11%
29. Bone Marrow 11%
30. Genes 11%
31. Thrombosis 9%
32. Androgen Receptors 9%
33. Carcinoma 9%
34. Exons 8%
35. Confidence Intervals 8%
36. Bone Marrow Transplantation 8%
37. Sarcoma 8%
38. Homologous Transplantation 8%
39. Renal Cell Carcinoma 7%
40. Ipilimumab 7%
41. Receptor Protein-Tyrosine Kinases 7%
42. Prednisone 7%
43. avelumab 7%
44. Apoptosis 7%
45. Prostatectomy 7%
46. Melanoma 7%
47. Mitoxantrone 7%
48. Recurrence 7%
49. Randomized Controlled Trials 6%
50. Venous Thrombosis 6%
51. regorafenib 6%
52. Biopsy 6%
53. Thrombocytopenia 6%
54. Graft vs Host Disease 6%
55. Neoplasm Metastasis 6%
56. Anticoagulants 6%
57. Stem Cell Transplantation 6%
58. Tissue Donors 6%
59. Unrelated Donors 6%
60. Stem Cells 6%
61. Proteins 6%
62. Hematopoietic Stem Cells 5%
63. Aplastic Anaemia 5%
64. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5%
65. Allogeneic Cells 5%
66. Pharmaceutical Preparations 5%
67. Quality of Life 5%
68. Population 5%
69. Growth 5%
70. Fanconi Anemia Complementation Group Proteins 5%
71. Fatigue 5%
72. Cyclophosphamide 5%